Navigation Links
Obesity Expert to Speak to FDA in Support of Treatment Options for Obese Patients
Date:9/15/2010

DENVER, Sept. 15 /PRNewswire/ -- On September 16, Denise Bruner, MD, FASBP will speak in favor of FDA approval for the new obesity drug Lorcaserin, during the open public hearing hour at the Endocrinologic and Metabolic Drug Advisory Committee meeting.

Dr. Bruner is a past president of the American Society of Bariatric Physicians (ASBP) and will speak to the committee on behalf of the Society's nearly 1,300 members throughout the U.S.  ASBP's physicians know from long experience that obesity can be a lifelong, chronic illness, which ultimately can produce very serious health risks and which can lower the quality of life of those afflicted.  

With recent obesity costs topping $147 billion per year, it is imperative that doctors be better equipped to treat obesity.  Research has shown that medical intervention can assist with weight loss and maintenance, and that weight loss can reverse or retard the development of diabetes, hypertension, sleep apnea and numerous other seriously harmful consequences of obesity.

Patients with obesity have few treatment options. While new obesity drugs are reviewed with great caution due to unexpected adverse reactions of past drugs, there is every reason to be confident that the clinical trials for Lorcaserin have adequately identified the relevant risks. Dr. Bruner, in speaking on behalf of the ASBP, will encourage the FDA advisory committee to consider the demonstrated effectiveness and benefits of this drug as thoroughly as it considers any risks.

About the ASBP

Founded in 1950, the ASBP is the oldest medical association focused on the education and training of medical professionals treating and managing obese patients and associated diseases. The ASBP is a collaborative organization that provides its members practical information and business tools to implement a successful medical bariatric practice. For more information about the ASBP, visit www.asbp.org.


'/>"/>
SOURCE ASBP
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Orexigen® Therapeutics COR-BMOD Study Published in the Journal Obesity
2. Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity From Its Broad Metabolic Disease Franchise at ADA Scientific Sessions
3. Zydus Novel Orally Administered GLP-1 Agonist - ZYOG1 to treat Diabetes and Obesity Enters Phase I Clinical Trial
4. Orexigen® Therapeutics Announces FDA Acceptance of Contrave® New Drug Application for the Treatment of Obesity
5. Gelesis Unveils Novel Non-Invasive Capsulated Device for Obesity and Presents Clinical Data; Appoints Former Pfizer R&D President to Board
6. Amylin and Takeda Announce Decision to Advance Development of Pramlintide/Metreleptin Combination Treatment for Obesity
7. VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity
8. Lightlake Therapeutics Inc Receives Ethical Approval to Begin Subject Selection for Future Phase II Clinical Trial for New Obesity Drug, in Helsinki, Finland
9. Obesity Significantly Increases Side Effects of Stereotactic Body Radiation Therapy in Lung Cancer Patients
10. Additional Data from the Qnexa Phase 3 Studies Presented at The Obesity Society 27th Annual Scientific Meeting
11. Orexigen(R) Therapeutics Releases New Efficacy Data for Contrave(R) in Late Breaker Presentations at the 27th Annual Scientific Meeting of The Obesity Society
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... SEATTLE , Jan. 24, 2017  CTI BioPharma ... that Michael A. Metzger has been appointed ... experience leading and growing companies in the biopharmaceutical industry ... pleased to welcome Michael to the Board of CTI ... CEO of CTI BioPharma. "Michael is an accomplished leader ...
(Date:1/24/2017)... 24, 2017 When tragedy strikes, victims often can,t communicate, ... conditions they have, and who back home is wondering about them. ... informed about the safety of their family and friends, while helping ... in times of crisis. ... If you find yourself or your family in one of ...
(Date:1/24/2017)... 24, 2017 Trifecta Clinical , a ... appointing Rick Ward to Vice President of ... is also announcing the promotion of Ericka Atkinson ... Rick joins Trifecta from Greenphire where he ... senior business development positions within the healthcare industry throughout ...
Breaking Medicine Technology:
(Date:1/24/2017)... Santa Rosa, California (PRWEB) , ... January 24, 2017 , ... ... named Cary McNamara as chief financial officer. , “Cary’s broad financial ... individual who possesses both the strategic planning and day-to-day financial operations skills we need ...
(Date:1/24/2017)... ... January 24, 2017 , ... The Cruise Web ... as part of the line’s 4th Annual MSC True Partnerships’ Awards. , ... American travel partners for the year based on overall business growth in revenue and ...
(Date:1/24/2017)... Baltimore, MD (PRWEB) , ... January 24, 2017 ... ... applicants to advance to the semi-final round of the 2017 Cupid's Cup Entrepreneurship ... competition celebrates its 12th year in 2017. The entrepreneurs will showcase their businesses ...
(Date:1/24/2017)... ... January 24, 2017 , ... West’s Health ... annual Solutions Series of webinars will start January 31 with a session about ... of current health and benefits topics, including employee engagement, pricing transparency, population health ...
(Date:1/24/2017)... ... , ... His message has been heard by more than 100,000 students and ... , Joel Feldman, has reached his biggest national audience yet: the three million daily ... newspapers in circulation in the country, and he hopes it will help spread his ...
Breaking Medicine News(10 mins):